Among these genes, IDH-mutant gliomas differed fundamentally from IDH-wildtype gliomas in terms of metabolism, epigenetics, biological behavior, aggressive invasion, susceptible population, and responsiveness to therapy (38–41). The gene discussed is IDH1; the disease is central nervous system cancer.